Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 March 2008, Vol. 111, No. 5, pp. 2516-2520.
Prepublished online as a Blood First Edition Paper on November 1, 2007; DOI 10.1182/blood-2007-10-116129.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2007-10-116129v1
111/5/2516    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Kumar, S. K.
Right arrow Articles by Gertz, M. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kumar, S. K.
Right arrow Articles by Gertz, M. A.
Related Collections
Right arrow Free Research Articles
Right arrow Clinical Trials and Observations
Right arrowRelated Article in Blood Online
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

CLINICAL TRIALS AND OBSERVATIONS

Improved survival in multiple myeloma and the impact of novel therapies

Shaji K. Kumar1, S. Vincent Rajkumar1, Angela Dispenzieri1, Martha Q. Lacy1, Suzanne R. Hayman1, Francis K. Buadi1, Steven R. Zeldenrust1, David Dingli1, Stephen J. Russell1, John A. Lust1, Philip R. Greipp1, Robert A. Kyle1, and Morie A. Gertz1

1 Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN

Treatments for myeloma have expanded in the last decade, but it is not clear if the introduction of novel therapies and the increased use of high-dose therapy have translated into better outcome for patients with myeloma. We examined the outcome of 2 groups of patients seen at a single institution, one from time of diagnosis and the other from the time of relapse, to examine the survival trends over time. Among 387 patients relapsing after stem-cell transplantation, a clear improvement in overall survival from the time of relapse was seen, with those relapsing after 2000 having a median overall survival of 23.9 versus 11.8 months (P < .001) for those who relapsed prior to this date. This improvement was independent of other prognostic factors. Patients treated with one or more of the newer drugs (thalidomide, lenalidomide, bortezomib) had longer survival from relapse (30.9 vs 14.8 months; P < .001). In a larger group of 2981 patients with newly diagnosed myeloma, those diagnosed in the last decade had a 50% improvement in overall survival (44.8 vs 29.9 months; P < .001). In this study, we demonstrate improved outcome of patients with myeloma in recent years, both in the relapsed setting as well as at diagnosis.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

The road to cure in multiple myeloma
Irene M. Ghobrial and Kenneth C. Anderson
Blood 2008 111: 2503. [Full Text] [PDF]





click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020